Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

51.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Is Viking Therapeutics Stock a Buy?
Its potential is looking increasingly more likely to be realized. 
Via The Motley Fool
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.
Viking Therapeutics has a promising anti-obesity treatment that is generating a lot of interest. 
Via The Motley Fool
3 Stock Winners That Are Up 1,000% or More in 2024
Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three. 
Via InvestorPlace
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ: HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. 
Via Benzinga
Why Viking Therapeutics Stock Is Plunging Today
The sell-off could present a buying opportunity for aggressive investors willing to bet that the obesity market will be big enough for multiple winners. 
Via The Motley Fool
Novo Nordisk Jumps On Strong Results For New Weight-Loss Drug
Amycretin showed a 13.1% weight loss after 12 weeks in a phase 1 trial. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant
The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher 
Via MarketBeat
Exposures Product Safety
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
A new player in the multibillion-dollar weight-loss drug market could be waiting in the wings. 
Via The Motley Fool
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
Here's why I'm not worried. 
Via The Motley Fool
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
One is a reigning champion, and the other is a burgeoning contender. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?
It could have even further to rise after its massive run-up. 
Via The Motley Fool
Beyond the "Mag 7": 3 Risk-On Market Forces
The biggest bear argument over the past year has been slim leadership in the market, namely concentrated in mega-cap tech stocks such as the “Mag 7.” However, dig deeper, and you will discover there's... 
Via Talk Markets
Better Buy: Eli Lilly vs. Viking Therapeutics
These two biotechs could eventually go head to head in a fast-growing market. 
Via The Motley Fool
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
The battle for the obesity therapies market is escalating. 
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
A favorite of both investors and analysts gets a boost from a bullish move by a pundit. 
Via The Motley Fool
Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review
The Nasdaq is on the cusp of setting a record high. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viking Therapeutics: A Teachable Moment About Investing for the Long Term
The biotherapeutics company's weight loss candidate scored a major win this week. 
Via The Motley Fool
Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?
Viking stock surged in the triple digits in one trading session. 
Via The Motley Fool
Is Viking Therapeutics a Buy Now?
The stock recently jumped more than 100% overnight thanks to surprising results from its anti-obesity candidate. 
Via The Motley Fool
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined... 
Via Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
The company reported in-line sales for the fourth quarter, but shares soared by double digits. 
Via Investor's Business Daily
Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say
Viking Therapeutics achieves significant weight loss in the VENTURE trial, outperforming rivals in body weight reductions. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.